Bio-Techne Corporation TECH

Revenue Intelligence Report • 68 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30

Bio-Techne Corporation's latest quarterly revenue is $321M for the period ending 2026-06-30. The model projects $1.2B across the next four quarters (-0.8% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 0.6%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The GAM forecast is based on reported revenue and SG&A data through 2026-06-30. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters
$1.20B
-0.8% YoY
SG&A Elasticity
0.49x
Training Fit
4.0% MAPE
Retrospective holdout (Q4 FY2026): The model predicted $319.2M vs the actual $321.2M — an error of 0.6%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.
Note: Bio-Techne Corporation does not report R&D expenses separately. The model uses the available expense measure without a separate R&D term.

Revenue Forecast

TECH Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 FY2026
Period end 2026-06-30		 $319.2M $321.2M $276.6M–$368.3M +0.7% ✓ In range
Q1 FY2027
Period end 2026-09-30		 $297.6M $260.9M–$339.5M +3.9%
Q2 FY2027
Period end 2026-12-31		 $296.4M $257.3M–$341.4M +0.2%
Q3 FY2027
Period end 2027-03-31		 $294.6M $252.9M–$343.1M -5.4%
Q4 FY2027
Period end 2027-06-30		 $316.2M $263.6M–$379.3M -1.6%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Bio-Techne Corporation's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Jul–Sep) 0.9621 -3.8% -3.8% below trend 17
FQ2 (Oct–Dec) 0.9724 -2.8% In line with trend 17
FQ3 (Jan–Mar) 1.0389 +3.9% +3.9% above trend 17
FQ4 (Apr–Jun) 1.0321 +3.2% +3.2% above trend 16

Spending and Revenue

TECH Spending Timing
Reading this chart: Each line shows the cumulative revenue association with a 1% change in spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 68 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.1302x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.
Enhanced forecast: The time-varying model (GAM) was selected using training fit, before evaluating the withheld quarter. Its holdout error is -0.6%.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. SEC source data. Forecast model: GAM; spending associations: ARDL (log-log) with 68 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

IQV BDX PODD BSX CI HSIC ALGN BIIB